A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency
Study Identifier
S245.3.123
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Scientific Result Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
20+ years
Protocol Summary
This study is to evaluate the safety of 3.0 g/day of SA-001 (to be flexibly increased or
decreased with the range from 1.5 g/day to 6.0 g/day), which will orally be administered for
52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in
the non-compensatory stage or by pancreatectomy.
Study Locations
Location
Status
Location
Site Reference ID/Investigator# 45211
Fukuoka, Japan
Status
Not applicable
Location
Site Reference ID/Investigator# 45297
Fukuoka, Japan
Status
Not applicable
Location
Site Reference ID/Investigator# 45220
Hiroshima, Japan
Status
Not applicable
Location
Site Reference ID/Investigator# 45279
Hiroshima, Japan
Status
Not applicable
Location
Site Reference ID/Investigator# 45223
Hokkaido, Japan
Status
Not applicable
Location
Site Reference ID/Investigator# 45303
Hokkaido, Japan
Status
Not applicable
Showing {first} - {last} of {total} Results